Immunosuppression in IDDM: Rationale, Risks, Benefits, and Strategies

Mahon, Jeffrey L; Dupré, John; Stiller, Calvin R; Donner, Allan P

doi:10.2337/diacare.13.7.806

Article navigation

Editorials| July 01 1990

Immunosuppression in IDDM: Rationale, Risks, Benefits, and Strategies

Jeffrey L Mahon, FRCP;

Jeffrey L Mahon, FRCP

University of Western Ontario, University Hospital

London, Ontario, Canada

Search for other works by this author on:

This Site

PubMed

Google Scholar

John Dupré, FRCP;

John Dupré, FRCP

University of Western Ontario, University Hospital

London, Ontario, Canada

Search for other works by this author on:

This Site

PubMed

Google Scholar

Calvin R Stiller, FRCP;

Calvin R Stiller, FRCP

University of Western Ontario, University Hospital

London, Ontario, Canada

Search for other works by this author on:

This Site

PubMed

Google Scholar

Allan P Donner, PhD

University of Western Ontario, University Hospital

London, Ontario, Canada

Search for other works by this author on:

This Site

PubMed

Google Scholar

Address correspondence and reprint requests to Dr. John Dupré, University Hospital, 339 Windermere Road, London, Ontario N6A 5A5, Canada.

Diabetes Care 1990;13(7):806–808

https://doi.org/10.2337/diacare.13.7.806

PubMed:

2201503

Immunosuppression in IDDM: Rationale, Risks, Benefits, and Strategies

Article PDF first page preview

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Immunosuppression in IDDM: Rationale, Risks, Benefits, and Strategies

Article PDF first page preview

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only